News-Medical.Net on MSN
Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity
By Hugo Francisco de Souza Can combining two gut hormone pathways unlock better obesity treatments? In the first human trial ...
Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial. This is an ASCO Meeting Abstract from the 2023 ...
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s ...
This randomized, parallel-group, phase II study included a safety run-in and a subsequent randomized phase. Eligible patients (cT3N+M0 or cT4NanyM0) received long-course nCRT (45-50.4 Gy in 25-28 ...
Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for the treatment of ...
A positive finerenone readout in non-diabetic CKD would extend Bayer’s cardiorenal franchise beyond current diabetic CKD use, supporting sentiment for BAYRY by opening a broader addressable market. It ...
Objective To determine whether liquefied petroleum gas (LPG) can reduce perinatal mortality in a setting with high reliance on biomass fuels for cooking.Design Community-based two-arm parallel cluster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results